Diamyd Medical's licensee reports progress with GAD in Parkinson

Neurologix Inc., a biotech company engaged in gene therapy, reports that they
have initiated a Phase II study with the GAD-gene within Parkinson's disease.
The right to use the GAD-gene has been licensed from Diamyd.

”These are very positive news for Diamyd, and the fact that GAD can be used
within additional therapeutic areas, not only within diabetes, predicts an
exciting future for us. That GAD is also used for neurological disorders opens
up for further new licensing possibilities”, says Elisabeth Lindner, President
and CEO at Diamyd.

Neurologix and Diamyd signed the license agreement in August 2006. It is a
running agreement with milestone payments and royalty on sales.

For more information, please contact:
Elisabeth Lindner, President and CEO Diamyd Medical AB (publ.),
Phone: +46-8-661 0026

For pictures and press material, please contact:
Sonja Catani, Chief Communications Officer Diamyd Medical AB,
Phone: +46-8-661 00 26

Diamyd Medical AB (publ.)
Linnégatan 89 B, SE-115 23 Stockholm, Sverige. Tel: +46 8 661 00 26, Fax: +46 8
661 63 68
E-post: info@diamyd.com. VATno: SE556530-142001.

Diamyd Medical is a Swedish biopharmaceutical company focusing on development of
 pharmaceuticals for treatment of autoimmune diabetes and its complications. The
company's most advanced project is the GAD-based drug Diamyd® for type 1
diabetes and  for which Phase III trials have been initiated in both the US and
Europe. Furthermore the company has initiated clinical studies within chronic
pain, using its Nerve Targeting Drug Delivery System (NTDDS). The company has
also out-licensed the use of GAD for the treatment of Parkinson's disease.

Diamyd Medical has offices in Sweden and in the US. The share is quoted on the
OMX Stockholm Nordic Exchange (ticker: DIAM B) and on OTCQX in the US (ticker:
DMYDY) administered by the Pink Sheets and the Bank of New York (PAL). Further
information is available on the company's web site: www.diamyd.com

This information is disclosed in accordance with the Securities Markets Act, the
Financial Instruments Trading Act or demands made in the exchange rules.